Press-release for stocks related to biomidwest for abbv

Prices are updated after-hours

tags : Biomidwest symbols : Abbv

save search

AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27 (Crawled : 13:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| -7.5% | O: 0.13% H: 0.0% C: 0.0%
conference abbvie health care

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
Published: 2024-02-27 (Crawled : 13:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| -7.5% | O: 0.13% H: 0.0% C: 0.0%
epkinly drug review food grants

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Published: 2024-02-02 (Crawled : 14:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 0.95% | O: 3.59% H: 0.0% C: 0.0%
abbvie financial results

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
Published: 2023-12-05 (Crawled : 15:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 15.19% | O: 0.51% H: 0.68% C: 0.32%
abbvie intelligence research collaboration

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 18.79% | O: -0.73% H: 0.78% C: 0.35%
lung abbvie positive cancer cell topline trial results

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 10.76% | O: 0.19% H: 0.0% C: 0.0%
disease abbvie research week

AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Published: 2023-09-12 (Crawled : 14:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 10.82% | O: 0.31% H: 0.07% C: -0.15%
skyrizi disease study

AbbVie to Present at the Morgan Stanley Healthcare Conference - September 6, 2023
Published: 2023-09-06 (Crawled : 14:30) - biospace.com/
MS | News | $90.66 0.44% 0.07% 8.1M

Finance

| 5.62% | O: -1.87% H: 0.0% C: 0.0%
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 13.05% | O: -0.1% H: 0.0% C: 0.0%
conference abbvie

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-07-21 (Crawled : 09:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 16.15% | O: 0.3% H: 0.0% C: 0.0%
tepkinly abbvie chmp positive treatment

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
Published: 2022-12-06 (Crawled : 14:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 0.74% | O: 0.05% H: 0.22% C: -0.19%
collaboration immunology therapeutics

AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
Published: 2022-11-08 (Crawled : 21:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 11.52% | O: 0.49% H: 1.88% C: -0.2%

AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 12.31% | O: 1.12% H: 1.9% C: 1.47%
meeting

AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference
Published: 2022-07-25 (Crawled : 13:20) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 11.23% | O: 0.18% H: 0.0% C: 0.0%
conference

AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 19.79% | O: 1.48% H: 0.0% C: 0.0%
treatment fda expansion drug label application migraine

AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
Published: 2022-05-16 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 7.58% | O: 0.53% H: 0.0% C: 0.0%
week disease

AbbVie's Rinvoq Breaks into Gastroenterology Space with UC Approval
Published: 2022-03-17 (Crawled : 15:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 5.84% | O: 0.72% H: 0.92% C: 0.9%
space approval rinvoq spac

VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 35.52% | O: 0.28% H: 1.84% C: 1.59%
fda eye drop presbyopia

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 41.38% | O: -0.35% H: 0.0% C: 0.0%
ema europe application disease risankizumab

AbbVie to Present at the Piper Sandler Healthcare Conference
Published: 2021-11-23 (Crawled : 14:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| 42.39% | O: 0.47% H: 0.0% C: 0.0%
conference